Natasha B Leighl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3951331/publications.pdf

Version: 2024-02-01

322 papers	28,534 citations	14614 66 h-index	5965 160 g-index
323 all docs	323 docs citations	323 times ranked	32168 citing authors

#	Article	IF	Citations
1	Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer. Neuro-Oncology Practice, 2022, 9, 50-58.	1.0	4
2	Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Nonâ€"Small Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 72-81.	1.1	17
3	CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 2022, 17, 434-445.	0.5	21
4	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. Journal of Thoracic Oncology, 2022, 17, 661-674.	0.5	9
5	Effects of Ethnicity on Outcomes of Patients With EGFR Mutationâ€"Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection. JTO Clinical and Research Reports, 2022, 3, 100259.	0.6	1
6	Importance of tumor size in resectable stage III-N2 nonâ€"small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 629-636.	0.4	2
7	Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. Cancer Treatment and Research Communications, 2022, 31, 100534.	0.7	3
8	Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. British Journal of Cancer, 2022, 127, 592-602.	2.9	36
9	Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data. Oncologist, 2022, 27, 675-684.	1.9	4
10	Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. Current Oncology, 2022, 29, 4428-4437.	0.9	5
11	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. Current Oncology, 2022, 29, 4981-4997.	0.9	14
12	Therapy for Stage IV Nonâ€"Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. Journal of Clinical Oncology, 2022, 40, 3323-3343.	0.8	63
13	Therapy for Stage IV Nonâ€"Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. Journal of Clinical Oncology, 2022, 40, 3310-3322.	0.8	60
14	Nazartinib for treatment-naive EGFR-mutant nonâˆ'small cell lung cancer: Results of a phase 2, single-arm, open-label study. European Journal of Cancer, 2022, 172, 276-286.	1.3	4
15	A Phase II Study of Telisotuzumab Vedotin in Patients With câ€"MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical Lung Cancer, 2021, 22, 170-177.	1.1	41
16	Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III nonâ€"small cell lung cancer: A real-world multicentre study. European Journal of Cancer, 2021, 142, 83-91.	1.3	48
17	Can Oncologists Predict the Efficacy of Treatments in Randomized Trials?. Oncologist, 2021, 26, 56-62.	1.9	11
18	The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. Quality of Life Research, 2021, 30, 445-454.	1.5	6

#	Article	IF	Citations
19	Lorlatinib in ALK-Rearranged Lung Cancer. Cancer Cell, 2021, 39, 25-27.	7.7	7
20	Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncology, The, 2021, 22, 190-197.	5.1	34
21	Meeting Immunotherapy Resistance in Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 187-190.	0.5	6
22	Therapy for Stage IV Nonâ€"Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2021, 39, 1040-1091.	0.8	192
23	Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials. Clinical Trials, 2021, 18, 500-504.	0.7	2
24	Automated imaging-based stratification of early-stage lung cancer patients prior to receiving surgical resection using deep learning applied to CTs.. Journal of Clinical Oncology, 2021, 39, 1552-1552.	0.8	1
25	Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. Lung Cancer, 2021, 156, 76-81.	0.9	7
26	The effect of prior cancer on nonâ€small cell lung cancer trial eligibility. Cancer Medicine, 2021, 10, 4814-4822.	1.3	4
27	An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e1-e12.	1.8	62
28	Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. Clinical Lung Cancer, 2021, 22, 253-259.	1.1	47
29	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Nonâ€"Small Cell Lung or Colorectal Cancer. JAMA Network Open, 2021, 4, e2117547.	2.8	20
30	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. Journal of Thoracic Oncology, 2021, 16, 2040-2050.	0.5	26
31	Amivantamab in EGFR Exon 20 Insertionâ€"Mutated Nonâ€"Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 2021, 39, 3391-3402.	0.8	320
32	Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre. Clinical Lung Cancer, 2021, , .	1.1	2
33	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). , 2021, 9, e002973.		26
34	Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancerâ€"A Cost-Efficient Strategy in a Public Healthcare System. Current Oncology, 2021, 28, 3268-3279.	0.9	12
35	Systemic Inflammatory Markers of Survival in Epidermal Growth Factorâ€"Mutated Nonâ€"Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. Clinical Lung Cancer, 2021, 22, 390-407.	1.1	7
36	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer. JAMA Oncology, 2021, 7, 1368.	3.4	57

#	Article	IF	Citations
37	Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data. Clinical Lung Cancer, 2021, , .	1.1	1
38	Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada. Journal of Thoracic Disease, 2021, 13, 5419-5429.	0.6	2
39	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	0.5	274
40	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. Cancers, 2021, 13, 5299.	1.7	2
41	Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. Journal of Molecular Biology, 2021, 433, 167294.	2.0	4
42	Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage 3 non-small cell lung cancer: safety and efficacy. JTO Clinical and Research Reports, 2021, 2, 100251.	0.6	3
43	End-to-End Nonâ€"Small-Cell Lung Cancer Prognostication Using Deep Learning Applied to Pretreatment Computed Tomography. JCO Clinical Cancer Informatics, 2021, 5, 1141-1150.	1.0	2
44	Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Current Oncology, 2021, 28, 4552-4576.	0.9	4
45	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110563.	1.4	6
46	The financial impact of cancer care on renal cancer patients. Canadian Journal of Urology, 2021, 28, 10762-10767.	0.0	0
47	Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. Current Oncology, 2021, 28, 5278-5294.	0.9	5
48	Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario. Journal of Oncology Pharmacy Practice, 2020, 26, 379-385.	0.5	1
49	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. Oncologist, 2020, 25, 64-77.	1.9	30
50	Development of the Functional Assessment of Cancer Therapyâ€"Immune Checkpoint Modulator (FACTâ€ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer, 2020, 126, 1550-1558.	2.0	26
51	Value assessment of oncology drugs using a weighted criterionâ€based approach. Cancer, 2020, 126, 1530-1540.	2.0	13
52	Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases. Advances in Radiation Oncology, 2020, 5, 350-357.	0.6	12
53	Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. European Journal of Cancer, 2020, 125, 49-57.	1.3	45
54	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology, 2020, 15, 404-415.	0.5	102

#	Article	IF	Citations
55	Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 2043-2054.e9.	0.4	16
56	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. Cancer Cell, 2020, 38, 602-604.	7.7	6
57	Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer, 2020, 147, 123-129.	0.9	95
58	Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 2706-2712.	0.6	10
59	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq1 1 0.784314 rgBT /Overlo	5.1	68
60	Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensiveâ€Stage Small Cell Lung Cancer. Oncologist, 2020, 25, 981-992.	1.9	23
61	Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Nonâ€"Small-Cell Lung Cancer: CheckMate 153. Journal of Clinical Oncology, 2020, 38, 3863-3873.	0.8	119
62	Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 1783.	1.3	2
63	Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. Lung Cancer, 2020, 150, 159-163.	0.9	33
64	Molecular testing for lung adenocarcinoma: Is it time to adopt a â€œplasmaâ€firstâ€•approach?. Cancer, 2020, 126, 3176-3180.	2.0	14
65	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. Cancer Cell, 2020, 37, 742-745.	7.7	51
66	Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. JCO Precision Oncology, 2020, 4, 520-533.	1.5	9
67	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. Lung Cancer, 2020, 146, 78-85.	0.9	24
68	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. Lung Cancer, 2020, 146, 350-354.	0.9	14
69	Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain Metastases. Journal of Pain and Symptom Management, 2020, 60, 422-429.e1.	0.6	21
70	Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. CMAJ Open, 2020, 8, E191-E198.	1.1	15
71	Advancing the systemic therapy of lung cancer: quality or quantity?. Lancet Oncology, The, 2020, 21, 322-324.	5.1	2
72	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respiratory Medicine,the, 2020, 8, 561-572.	5.2	47

#	Article	IF	Citations
73	A drug discovery platform to identify compounds that inhibit EGFR triple mutants. Nature Chemical Biology, 2020, 16, 577-586.	3.9	30
74	Cancer patientsâ€™ experiences with immune checkpoint modulators: A qualitative study. Cancer Medicine, 2020, 9, 3015-3022.	1.3	21
75	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2020, 38, 1608-1632.	0.8	301
76	Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Cancer Treatment Reviews, 2020, 85, 101979.	3.4	21
77	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. Clinical Lung Cancer, 2020, 21, e488-e492.	1.1	5
78	TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.. Journal of Clinical Oncology, 2020, 38, 3050-3050.	0.8	1
79	Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in populationâ€based reflex testing. Cancer, 2019, 125, 4043-4051.	2.0	14
80	Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. Molecular Carcinogenesis, 2019, 58, 1960-1973.	1.3	1
81	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1228-1237.	1.1	11
82	Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Nonâ€“Small Cell Lung Cancer, Including Patients Aged 70ÂYearsÂor Older or with Poor Performance Status (CheckMate 153). Journal of Thoracic Oncology, 2019, 14, 1628-1639.	0.5	137
83	Improving the Management of Brain Metastases in Oncogene-Addicted Nonâ€“Small-Cell Lung Cancer. Journal of Oncology Practice, 2019, 15, 571-572.	2.5	0
84	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. JNCI Cancer Spectrum, 2019, 3, pkz071.	1.4	4
85	Realâ€world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced nonâ€small cell lung cancer. Cancer Medicine, 2019, 8, 7542-7555.	1.3	14
86	Five-Year Overall Survival for Patients With Advanced Nonâ€'Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 2019, 37, 2518-2527.	0.8	811
87	Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer, 2019, 134, 259-267.	0.9	28
88	Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. Oncotarget, 2019, 10, 1760-1774.	0.8	25
89	Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 4691-4700.	3.2	401
90	The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. Lung Cancer, 2019, 131, 86-89.	0.9	14

#	Article	IF	Citations
91	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respiratory Medicine,the, 2019, 7, 347-357.	5.2	137
92	Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System. Clinical Lung Cancer, 2019, 20, 231-236.	1.1	38
93	The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2019, 20, 21.	1.3	27
94	Hyperprogressive disease in earlyâ€phase immunotherapy trials: Clinical predictors and association with immuneâ€related toxicities. Cancer, 2019, 125, 1341-1349.	2.0	115
95	The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis. Oncologist, 2019, 24, e501-e509.	1.9	8
96	Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. Oncologist, 2019, 24, e510-e517.	1.9	10
97	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open, 2019, 4, e000532.	2.0	13
98	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e338-e345.	1.1	14
99	The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective. Cancer Cytopathology, 2019, 127, 72-78.	1.4	10
100	Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis, 2018, 39, 336-346.	1.3	29
101	Translation of Knowledge to Practiceâ€"Improving Awareness in NSCLC Molecular Testing. Journal of Thoracic Oncology, 2018, 13, 1004-1011.	0.5	8
102	Radical Treatment of Stage II Nonâ€“small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes. Clinical Lung Cancer, 2018, 19, e11-e18.	1.1	6
103	Chemotherapy and radiation treatment decision-making experiences of older adults with cancer: A qualitative study. Journal of Geriatric Oncology, 2018, 9, 47-52.	0.5	32
104	Personalized medicine for non-small cell lung cancer: where are we now and where can we go?. Expert Review of Respiratory Medicine, 2018, 12, 81-82.	1.0	5
105	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	0.8	2,691
106	Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 911-919.	0.8	387
107	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3290-3297.	0.8	515
108	Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature, 2018, 563, 579-583.	13.7	624

#	Article	IF	Citations
109	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. CNS Drugs, 2018, 32, 527-542.	2.7	10
110	Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2018, 19, 426-434.e1.	1.1	102
111	Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Nonâ€"small-cell Lung Cancer (NCT02788461). Clinical Lung Cancer, 2018, 19, e699-e703.	1.1	15
112	The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. Lung Cancer, 2018, 123, 22-29.	0.9	28
113	Additional germline findings from a tumor profiling program. BMC Medical Genomics, 2018, 11, 65.	0.7	16
114	Lung cancer in never smokers from the Princess Margaret Cancer Centre. Oncotarget, 2018, 9, 22559-22570.	0.8	20
115	The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy. Current Drug Targets, 2018, 20, 81-86.	1.0	5
116	ALK -Rearranged Nonâ€"Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. Clinical Lung Cancer, 2017, 18, 156-161.	1.1	78
117	Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. Clinical Lung Cancer, 2017, 18, 388-395.e4.	1.1	23
118	Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade. Clinical Lung Cancer, 2017, 18, 274-280.e6.	1.1	63
119	Indications for Adjuvant Mediastinal Radiotherapy in Surgically Resected Small Cell Lung Cancer. Annals of Thoracic Surgery, 2017, 103, 1647-1653.	0.7	26
120	P1.07-017 Indications for Adjuvant Mediastinal Radiation in Surgically Resected Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S706.	0.5	0
121	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. Journal of Thoracic Oncology, 2017, 12, 1210-1222.	0.5	112
122	Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209.	0.5	40
123	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nature Genetics, 2017, 49, 1126-1132.	9.4	472
124	Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. Therapeutic Advances in Medical Oncology, 2017, 9, 405-414.	1.4	35
125	P2.08-001 Giving a Voice to Patients and Caregivers through the Lung Cancer Canada â€˜Faces of Lung Cancerâ€™ Survey. Journal of Thoracic Oncology, 2017, 12, S1109.	0.5	0
126	P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial. Journal of Thoracic Oncology, 2017, 12, S1167-S1169.	0.5	11

#	Article	IF	Citations
127	P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1323-S1324.	0.5	0
128	OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate ofÂVenous Thromboembolism. Journal of Thoracic Oncology, 2017, 12, S326-S327.	0.5	0
129	OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II FindingsÂfrom the Placebo-Controlled LUME-Meso Trial. Journal of Thoracic Oncology, 2017, 12, S329-S330.	0.5	0
130	P1.05-069 Stage II NSCLC Treated with Non-Surgical Approaches: A Multi-Institution Report of Outcomes. Journal of Thoracic Oncology, 2017, 12, S657-S658.	0.5	0
131	P1.06-039 Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant. Journal of Thoracic Oncology, 2017, 12, S689-S690.	0.5	0
132	P1.07-016 Trends, Practice Patterns and Underuse of Surgery in the Treatment of Early Stage Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S705.	0.5	0
133	Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer. Radiotherapy and Oncology, 2017, 123, 195-202.	0.3	43
134	Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma. European Respiratory Journal, 2017, 49, 1601428.	3.1	33
135	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With AdvancedÂNonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 556-566.	0.5	40
136	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 1523-1531.	5.1	158
137	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. Pharmacoeconomics, 2017, 35, 1195-1209.	1.7	16
138	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1610-1623.	5.1	136
139	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). Lung Cancer, 2017, 111, 23-29.	0.9	160
140	Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study. Supportive Care in Cancer, 2017, 25, 879-886.	1.0	39
141	A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, e41-e47.	1.1	4
142	BRM Promoter Polymorphisms and Survival of Advanced Nonâ€"Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. Clinical Cancer Research, 2017, 23, 2460-2470.	3.2	8
143	Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. Oncologist, 2017, 22, 70-80.	1.9	58
144	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. Frontiers in Oncology, 2017, 7, 50.	1.3	30

#	Article	IF	Citations
145	Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 113.	1.3	46
146	Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. Journal of Oncology Practice, 2017, 13, 780-783.	2.5	3
147	Systemic Therapy for Stage IV Nonâ€"Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2017, 35, 3484-3515.	0.8	492
148	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinaseâ€"Positive Nonâ€"Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 2490-2498.	0.8	506
149	Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?. Journal of Clinical Oncology, 2017, 35, 2764-2771.	0.8	56
150	Curing Early-Stage Lung Cancer: Is There an Easy Way Out?. Journal of Oncology Practice, 2017, 13, 63-65.	2.5	0
151	Health utility scores (HUS) and health-related quality of life (HRQoL) in stage 4 lung cancer (S4LC) patients with brain metastases (BM).. Journal of Clinical Oncology, 2017, 35, 24-24.	0.8	1
152	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget, 2017, 8, 57528-57536.	0.8	7
153	A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget, 2017, 8, 69651-69662.	0.8	23
154	Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire.. Journal of Clinical Oncology, 2017, 35, 167-167.	0.8	0
155	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?â€"current evidence and future perspectives. Translational Lung Cancer Research, 2016, 5, 628-636.	1.3	15
156	How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment. BMJ Open, 2016, 6, e010981.	0.8	25
157	Patients with Advanced Nonâ€"Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?. Journal of Thoracic Oncology, 2016, 11, 79-84.	0.5	54
158	ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. Cancer Epidemiology, 2016, 41, 50-56.	0.8	7
159	Perceptions of palliative care among patients with advanced cancer and their caregivers. Cmaj, 2016, 188, E217-E227.	0.9	264
160	P2.39: Long-Term OS for Patients WithÂAdvanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. Journal of Thoracic Oncology, 2016, 11, S241-S242.	0.5	18
161	Early Palliative Care and Its Role in Oncology: A Qualitative Study. Oncologist, 2016, 21, 1387-1395.	1.9	39
162	Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. Oncologist, 2016, 21, 1450-1460.	1.9	101

#	Article	IF	Citations
163	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine, 2016, 8, 109.	3.6	211
164	The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy. European Journal of Cancer, 2016, 61, 85-93.	1.3	3
165	Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitorâ€"Induced Skin Toxicities in Patients With Metastatic Lung Cancer. Journal of Clinical Oncology, 2016, 34, 810-815.	0.8	79
166	Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 468-475.	0.4	124
167	Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. Future Oncology, 2016, 12, 9-23.	1.1	13
168	The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treatment Reviews, 2016, 45, 139-162.	3.4	187
169	Pointed Progress in Second-Line Advanced Nonâ€"Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. Journal of Clinical Oncology, 2016, 34, 1676-1688.	0.8	71
170	Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Nonâ€"Small Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 133-141.	1.1	10
171	Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 900-909.	0.5	27
172	Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. British Journal of Cancer, 2016, 114, 616-622.	2.9	17
173	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open, 2016, 1, e000118.	2.0	6
174	Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. Journal of Clinical Oncology, 2016, 34, 1532-1532.	0.8	2
175	E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLCâ€"Outcomes based on chemotherapy subsets.. Journal of Clinical Oncology, 2016, 34, 8507-8507.	0.8	15
176	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).. Journal of Clinical Oncology, 2016, 34, 9007-9007.	0.8	25
177	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. Journal of Clinical Oncology, 2016, 34, 9026-9026.	0.8	31
178	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. Journal of Clinical Oncology, 2016, 34, 9044-9044.	0.8	28
179	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. Journal of Clinical Oncology, 2016, 34, e20522-e20522.	0.8	7
180	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. Oncotarget, 2016, 7, 25632-25639.	0.8	9

#	Article	IF	Citations
181	Quality of life (QoL) for FDA-approved agents in advanced NSCLC.. Journal of Clinical Oncology, 2016, 34, e18117-e18117.	0.8	0
182	A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC.. Journal of Clinical Oncology, 2016, 34, TPS2609-TPS2609.	0.8	0
183	The economic impact of the transition from branded to generic oncology drugs.. Journal of Clinical Oncology, 2016, 34, 6520-6520.	0.8	0
184	Real-world EQ5D health utility values for metastatic lung cancer patients by molecular alteration and response to therapy.. Journal of Clinical Oncology, 2016, 34, 6567-6567.	0.8	0
185	Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer. Translational Cancer Research, 2016, 5, S458-S461.	0.4	0
186	Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor. Journal of Thoracic Oncology, 2015, 10, e100-e101.	0.5	28
187	Realâ€world chemotherapy treatment patterns in metastatic nonâ€“small cell lung cancer: Are patients undertreated?. Cancer, 2015, 121, 2562-2569.	2.0	71
188	Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. PLoS ONE, 2015, 10, e0121211.	1.1	16
189	Reply to G. Spitzer and M.A. Socinski. Journal of Clinical Oncology, 2015, 33, 525-526.	0.8	0
190	The Value of Personalizing Medicine: Medical Oncologistsâ€™ Views on Gene Expression Profiling in Breast Cancer Treatment. Oncologist, 2015, 20, 351-356.	1.9	27
191	Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2015, 33, 3199-3212.	0.8	680
192	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. Journal of Clinical Oncology, 2015, 33, 2472-2480.	0.8	94
193	A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 457-465.	1.1	41
194	Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Annals of Oncology, 2015, 26, 1415-1421.	0.6	187
195	Correlation of Dosimetric and Clinical Factors With the Development of Esophagitis and Radiation Pneumonitis in Patients With Limited-Stage Small-Cell Lung Carcinoma. Clinical Lung Cancer, 2015, 16, 216-220.	1.1	27
196	Pembrolizumab for the Treatment of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 2018-2028.	13.9	5,183
197	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. Journal of Oncology Practice, 2015, 11, 135-136.	2.5	20
198	Sunitinib: The Next Advance in Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2015, 33, 1637-1639.	0.8	3

#	Article	IF	Citations
199	Evan's Syndrome Associated with Pembrolizumab Therapy in Metastatic Non-Small Cell Lung Cancer. Blood, 2015, 126, 4543-4543.	0.6	8
200	Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 11060-11060.	0.8	2
201	Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. Journal of Thoracic Disease, 2015, 7, 1898-906.	0.6	17
202	Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now. Journal of Clinical Oncology, 2014, 32, 3330-3336.	0.8	80
203	Barriers and Challenges to Global Clinical Cancer Research. Oncologist, 2014, 19, 61-67.	1.9	30
204	Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC. Frontiers in Oncology, 2014, 4, 329.	1.3	33
205	Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. Frontiers in Oncology, 2014, 4, 258.	1.3	4
206	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in Oncology, 2014, 4, 204.	1.3	137
207	Two <scp>BRM</scp> promoter insertion polymorphisms increase the risk of earlyâ€stage upper aerodigestive tract cancers. Cancer Medicine, 2014, 3, 426-433.	1.3	16
208	A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The â€œSMARTâ€• Approach for Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2014, 9, 397-402.	0.5	117
209	Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. Journal of Thoracic Oncology, 2014, 9, 1449-1458.	0.5	45
210	Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing. Journal of Thoracic Oncology, 2014, 9, 947-956.	0.5	72
211	Reply to C.G. Azzoli et al and C. Chouaid et al. Journal of Clinical Oncology, 2014, 32, 3578-3579.	0.8	1
212	Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis, 2014, 17, 909-920.	3.7	40
213	Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Nonâ€“Small-Cell Lung Cancer. Journal of Oncology Practice, 2014, 10, e130-e136.	2.5	29
214	Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis. Clinical Lung Cancer, 2014, 15, 110-118.	1.1	49
215	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Nonâ€“Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. Clinical Lung Cancer, 2014, 15, 52-57.	1.1	32
216	Genetic markers of bevacizumab-induced hypertension. Angiogenesis, 2014, 17, 685-94.	3.7	24

#	Article	IF	Citations
217	Second-Line Therapy in Nonâ€"Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens. Journal of Clinical Oncology, 2014, 32, 1874-1881.	0.8	9
218	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. Journal of Clinical Oncology, 2014, 32, 3673-3679.	0.8	251
219	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 1379-1388.	5.1	119
220	Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Nonâ€"Small-Cell Lung Cancer: The Bar Is Dropping. Journal of Clinical Oncology, 2014, 32, 1407-1411.	0.8	44
221	Early-stage lung cancerâ€"what do the experts recommend?. Annals of Oncology, 2014, 25, 1451-1453.	0.6	1
222	Long-Term Outcome After Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet. Annals of Thoracic Surgery, 2014, 98, 962-967.	0.7	1
223	Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet, The, 2014, 383, 1721-1730.	6.3	1,361
224	A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer, 2014, 84, 289-294.	0.9	11
225	Home care utilization and costs in stage IV lung cancer: a Canadian public payer experience. Lung Cancer Management, 2014, 3, 439-442.	1.5	0
226	Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions. Lung Cancer Management, 2014, 3, 477-489.	1.5	0
227	Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. Journal of Clinical Oncology, 2014, 32, TPS7612-TPS7612.	0.8	1
228	End-of-life home care utilization and costs in patients with advanced colorectal cancer. Journal of Community and Supportive Oncology, 2014, 12, 92-98.	0.1	9
229	Satisfaction with oncology care among patients with advanced cancer and their caregivers. Quality of Life Research, 2013, 22, 2341-2349.	1.5	40
230	Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL). Supportive Care in Cancer, 2013, 21, 165-172.	1.0	31
231	Chemoradiotherapy for Locoregional Recurrence of Nonâ€"Small-Cell Lung Cancer After Surgical Resection: A Retrospective Analysis. Clinical Lung Cancer, 2013, 14, 200-204.	1.1	30
232	A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 19-27.	1.1	38
233	A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 747-755.	1.1	14
234	Long-Term Outcome after En Bloc Resection of Nonâ€"Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine. Journal of Thoracic Oncology, 2013, 8, 1538-1544.	0.5	36

#	Article	IF	Citations
235	Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Nonâ€"Small-Cell Lung Cancer in a Publicly Funded Health Care System. Journal of Thoracic Oncology, 2013, 8, 1136-1141.	0.5	42
236	Gefitinib: re-emerging from the shadows. Lung Cancer Management, 2013, 2, 423-437.	1.5	0
237	KRAS Mutations as Prognostic and Predictive Markers in Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 530-542.	0.5	104
238	Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?. Journal of Thoracic Oncology, 2013, 8, 366-368.	0.5	91
239	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. Journal of Clinical Oncology, 2013, 31, 8027-8027.	0.8	22
240	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. Journal of Clinical Oncology, 2013, 31, 8028-8028.	0.8	28
241	Willingness of patients to provide biologic samples for pharmacogenomic testing.. Journal of Clinical Oncology, 2013, 31, 6543-6543.	0.8	1
242	Closing the personalized medicine information gap: HER2 test documentation practice. American Journal of Managed Care, 2013, 19, 838-44.	0.8	5
243	Impact and Feasibility of a Comprehensive Geriatric Assessment in the Oncology Setting. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 322-328.	0.6	77
244	Angiogenesis inhibitors in lung cancer: beyond VEGF?. Lung Cancer Management, 2012, 1, 7-10.	1.5	0
245	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Nonâ€"Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1830-1844.	0.5	23
246	Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. Radiotherapy and Oncology, 2012, 102, 263-267.	0.3	14
247	Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. Value in Health, 2012, 15, 580-585.	0.1	14
248	Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer. Hormones and Cancer, 2012, 3, 93-100.	4.9	34
249	A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology, 2012, 69, 815-824.	1.1	6
250	The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 563-571.	1.1	16
251	A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7541-7541.	0.8	3
252	Cluster-randomized trial of early palliative care for patients with metastatic cancer.. Journal of Clinical Oncology, 2012, 30, 9003-9003.	0.8	9

#	Article	IF	Citations
253	Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2012, 30, 7586-7586.	0.8	0
254	The effect of two BRM promoter variantsÂon the risk of stage I/II upper aerodigestive tract cancers.. Journal of Clinical Oncology, 2012, 30, 10522-10522.	0.8	3
255	Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 1535-1535.	0.8	0
256	Social environment as a predictor of smoking cessation and recidivism in lung cancer survivors.. Journal of Clinical Oncology, 2012, 30, 9032-9032.	0.8	0
257	Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario.. Journal of Clinical Oncology, 2012, 30, 166-166.	0.8	0
258	Cancer patientsâ€™ and physiciansâ€™ preferences for decision making regarding pharmacogenomic testing (PGT).. Journal of Clinical Oncology, 2012, 30, 13-13.	0.8	1
259	Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments.. Journal of Clinical Oncology, 2012, 30, 75-75.	0.8	0
260	Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 537-544.	0.5	55
261	A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1379-1391.	0.5	89
262	Classification and Toxicities of Vascular Disrupting Agents. Clinical Lung Cancer, 2011, 12, 18-25.	1.1	30
263	Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Nonâ€"Small-Cell Lung Cancer: A California Cancer Consortium Trial. Clinical Lung Cancer, 2011, 12, 33-37.	1.1	18
264	Clinical Outcomes of Extensive Stage Small Cell Lung Carcinoma Patients Treated With Consolidative Thoracic Radiotherapy. Clinical Lung Cancer, 2011, 12, 375-379.	1.1	43
265	Determinants of quality of life in patients with advanced cancer. Supportive Care in Cancer, 2011, 19, 621-629.	1.0	70
266	Enhancing decision making about participation in cancer clinical trials: development of a question prompt list. Supportive Care in Cancer, 2011, 19, 1227-1238.	1.0	43
267	How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology, 2011, 12, 1-11.	1.3	12
268	EGFR gene status in cytological samples of nonsmall cell lung carcinoma. Cancer Cytopathology, 2011, 119, 80-91.	1.4	107
269	Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of Clinical Oncology, 2011, 29, 2077-2084.	0.8	95
270	Targeting the Phosphatidylinosital 3-Kinase, Akt, and Mammalian Target of Rapamycin Pathway in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, S1805-S1807.	0.5	3

#	Article	IF	Citations
271	Impact of New Chemotherapeutic and Targeted Agents on Survival in Stage IV Non-Small Cell Lung Cancer. Oncologist, 2011, 16, 1307-1315.	1.9	27
272	Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?. Journal of Oncology Practice, 2011, 7, 36s-45s.	2.5	12
273	Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL). Blood, 2011, 118, 2068-2068.	0.6	0
274	Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL). Journal of Thoracic Oncology, 2010, 5, 1970-1976.	0.5	105
275	A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2010, 5, 1054-1059.	0.5	84
276	The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials. Journal of Thoracic Oncology, 2010, 5, 640-648.	0.5	17
277	Targeting Vascular Endothelial Growth Factor in Lung Cancer. Journal of Thoracic Oncology, 2010, 5, S484-S486.	0.5	3
278	Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. Cancer, 2010, 116, 5694-5699.	2.0	48
279	Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Nonâ€"Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. Journal of Clinical Oncology, 2010, 28, 49-55.	0.8	231
280	A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium. Oncologist, 2010, 15, 810-818.	1.9	66
281	Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma. Journal of Clinical Oncology, 2010, 28, 3316-3322.	0.8	96
282	Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1953-1957.	0.5	56
283	Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 2010, 102, 298-306.	3.0	64
284	Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Nonâ€"Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial. Journal of Clinical Oncology, 2009, 27, 4268-4273.	0.8	38
285	Economic evaluation of docetaxel for breast cancer. Expert Opinion on Pharmacotherapy, 2009, 10, 283-290.	0.9	7
286	Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group. Journal of Thoracic Oncology, 2009, 4, 586-594.	0.5	18
287	Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 2009, 27, 1413-1418.	0.8	240
288	Venous thromboembolism and nonsmall cell lung cancer. Cancer, 2009, 115, 5516-5525.	2.0	72

#	Article	IF	Citations
289	Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 404-410.	0.8	144
290	Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Nonâ€"Small-Cell Lung Cancer: AVAiL. Journal of Clinical Oncology, 2009, 27, 1227-1234.	0.8	1,430
291	Initial Treatment Strategies and Outcomes for Multifocal Bronchioloalveolar Carcinoma. Clinical Lung Cancer, 2009, 10, 187-192.	1.1	3
292	Phase II Study of Preoperative Gefitinib in Clinical Stage I Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6229-6236.	0.8	93
293	A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium. Journal of Thoracic Oncology, 2009, 4, 1163-1169.	0.5	16
294	Improved compliance with adjuvant vinorelbine and cisplatin in non-small cell lung cancer. Hematology/ Oncology and Stem Cell Therapy, 2009, 2, 265-271.	0.6	6
295	A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Research and Treatment, 2008, 108, 87-92.	1.1	73
296	Development and evaluation of a decision aid for patients considering firstâ€line chemotherapy for metastatic breast cancer. Health Expectations, 2008, 11, 35-45.	1.1	35
297	Gefitinib: a consideration of cost. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 223-232.	0.7	0
298	Age and Comorbidity As Independent Prognostic Factors in the Treatment of Nonâ€"Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials. Journal of Clinical Oncology, 2008, 26, 54-59.	0.8	290
299	Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inletâ˜†. European Journal of Cardio-thoracic Surgery, 2008, 33, 1129-1134.	0.6	38
300	Factors Contributing to Adjuvant Therapy Decisions. Journal of Thoracic Oncology, 2008, 3, 195-196.	0.5	1
301	Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Nonâ€"Small-Cell Lung Cancerâ€"A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 2007, 25, 2256-2261.	0.8	45
302	Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer?. Journal of Thoracic Oncology, 2007, 2, 273-281.	0.5	51
303	Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 39-43.	0.5	43
304	Docetaxel in Non-Small Cell Lung Cancer. Drugs and Aging, 2007, 24, 411-428.	1.3	12
305	PD6-1-7: A phase II study of UCN-01 in combination with topotecan in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a study of the Princess Margaret Hospital phase II consortium (PMH-C).. Journal of Thoracic Oncology, 2007, 2, S427.	0.5	0
306	PD3-2-5: Preoperative gefitinib in clinical stage I NSCLC. Journal of Thoracic Oncology, 2007, 2, S464.	0.5	0

#	Article	IF	Citations
307	P3-120: Response rates of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) in clinical practice. Journal of Thoracic Oncology, 2007, 2, S730.	0.5	0
308	Venous Thromboembolism and Non-Small Cell Lung Cancer: A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials.. Blood, 2007, 110, 3995-3995.	0.6	0
309	A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2006, 51, 115-121.	0.9	32
310	Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer, 2006, 52, 327-332.	0.9	16
311	Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. Chest, 2005, 128, 2933-2943.	0.4	74
312	Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquidâ€"liquid extractions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 829, 45-49.	1.2	20
313	Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. Journal of Clinical Oncology, 2005, 23, 2831-2839.	0.8	159
314	Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis. Journal of Clinical Oncology, 2005, 23, 1278-1288.	0.8	463
315	Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature. Journal of Clinical Oncology, 2005, 23, 2926-2936.	0.8	335
316	Cancer Patient Preferences for Communication of Prognosis in the Metastatic Setting. Journal of Clinical Oncology, 2004, 22, 1721-1730.	0.8	428
317	Treatment Decision Aids in Advanced Cancer: When the Goal Is Not Cure and the Answer Is Not Clear. Journal of Clinical Oncology, 2004, 22, 1759-1762.	0.8	43
318	A Phase I Study of Pegylated Liposomal Doxorubicin Hydrochloride (Caelyxâ„¢) in Combination with Cyclophosphamide and Vincristine as Second-Line Treatment of Patients with Small-Cell Lung Cancer. Clinical Lung Cancer, 2003, 5, 107-112.	1.1	11
319	Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clinical Cancer Research, 2003, 9, 2241-7.	3.2	90
320	Cost-Effectiveness of Chemotherapy in Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 3750-3752.	0.8	4
321	Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 1344-1352.	0.8	51
322	Discussing Adjuvant Cancer Therapy. Journal of Clinical Oncology, 2001, 19, 1768-1778.	0.8	83